RxDoctor Payments Data

James Noth, MD

Ophthalmology · Westmont, ILNPI 1013067669

Payments from drug & device makers

$775in general payments, 2019–2025

Across 16 payments — averaging $48.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$238
  • Johnson & Johnson Surgical Vision, Inc.$183
  • Alcon$156
  • Rxsight Inc$88
  • Quidel Corporation$33
  • Glaukos Corporation$26
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 40th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$329,400
Medicare patients
1,029
Services billed
1,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj22$615,390
Prednisolone Acetate397$13,003
CombiganBrimonidine Tartrate/Timolol12$6,766
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$6,219
Timolol Maleate158$5,791
Latanoprost301$5,295
SimbrinzaBrinzolamide/Brimonidine Tart12$4,465
Brimonidine Tartrate93$2,990
Ketorolac Tromethamine177$2,415
Ofloxacin195$2,028
ValacyclovirValacyclovir Hcl25$1,355
Dorzolamide Hcl69$1,049
MoxifloxacinMoxifloxacin Hcl12$899
Doxycycline Monohydrate45$856
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$15$615,39022 claims
AlconSimbrinza$156$4,46512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Westmont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →